Over 20 years ago, it was first proposed that autoinflammation underpins a handful of rare
monogenic disorders characterized by recurrent fever and systemic inflammation. The …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

Autoinflammatory diseases were first recognized nearly 20 years ago as distinct clinical and
immunological entities caused by dysregulation in the innate immune system. Since then …

Interleukin-1 (IL-1) is a central mediator of innate immunity and inflammation. The IL-1 family
includes seven ligands with agonist activity (IL-1α and IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL …

Our immune system is based on the close collaboration of the innate and adaptive immune
systems for the rapid detection of any threats to the host. Recognition of pathogen-derived …

Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-
1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory …

Autoinflammatory diseases are conditions in which pathogenic inflammation arises primarily
through antigen-independent hyperactivation of immune pathways. First recognized just …

Abstract The interleukin (IL)-1 family of cytokines comprises 11 members, including 7 pro-
inflammatory agonists (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ) and 4 defined or …

Interleukin-18 (IL-18) is a member of the IL-1 family of cytokines. Similar to IL-1β, IL-18 is
synthesized as an inactive precursor requiring processing by caspase-1 into an active …

Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …